Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bromocriptine for Prediabetes in Schizophrenia
NCT03575000Phase 4Not yet recruiting
- Sponsor
- VA Pittsburgh Healthcare System
- Start
- Jan 2026
- Primary completion
- Jul 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of bromocriptine in prediabetes and insulin resistance (IR), sponsored by VA Pittsburgh Healthcare System. Primary endpoint: Homeostatic Model Assessment for Insulin Resistance at 10 weeks. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
bromocriptine
03
Conditions
prediabetesinsulin resistance (IR)
Beyond the preview
Go deeper on NCT03575000.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03575000.